https://www.selleckchem.com/pr....oducts/ddr1-in-1.htm
ers and therapies in PD. ANN NEUROL 2021;89546-559. COVID-19 pandemic causes high global morbidity and mortality and better medical treatments to reduce mortality are needed. To determine the added benefit of cyclosporine A (CsA), to low-dose steroid treatment, in patients with COVID-19. Open-label, non randomized pilot study of patients with confirmed infection of SARS-CoV-2 hospitalized from April to May 2020 at a single centre in Puebla, Mexico. Patients were assigned to receive either steroids or CsA plus steroids. Pneumonia sever
Tycka om
Kommentar
Dela med sig
